Please login to the form below

Not currently logged in


This page shows the latest Aduhelm news and features for those working in and with pharma, biotech and healthcare.

Biogen retracts EMA application for Alzheimer's drug Aduhelm

Biogen retracts EMA application for Alzheimer's drug Aduhelm

thus far would not be enough to support a positive opinion on the marketing authorisation of Aduhelm by the regulator. ... said the results ‘did not show overall that Aduhelm was effective at treating adults with early stage Alzheimer’s disease’.

Latest news

More from news
Approximately 18 fully matching, plus 7 partially matching documents found.

Latest from PMHub

  • Article

    In her latest article for PME Magazine, Rachel Howard explores the implications for P&R decisions in EU countries following the FDA’s recent approval of Aduhelm as a treatment for

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs


Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

Environment: where does the pharmaceutical industry stand?
The communication challenge of helping he next generation to be healthier
As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
Are we losing sight of what the democratisation of healthcare really looks like?
We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...